1.96

7.98% -0.17

Pre-market: 1.96

Protalix BioTherapeutics Inc. (PLX)

Overview News Price History Option Chain Discussions Forecast Stock Split

Protalix BioTherapeutics Inc. stock is traded at $1.96, with a volume of 1.93M. It is down -7.98% in the last 24 hours and down -8.84% over the past month. Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase IIa clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.

Previous Close:

$2.13

Open:

$2.13

24h Volume:

1.93M

Relative Volume:

1.62

Market Cap:

$157.92M

Revenue:

$52.74M

Net Income/Loss:

$-6.60M

P/E Ratio:

-23.20

EPS:

-0.0845

Net Cash Flow:

$-13.63M

1W Performance:

-7.55%

1M Performance:

-8.84%

6M Performance:

-17.65%

1Y Performance:

-30.99%

1-Day Range:

$1.925

$2.1725

1-Week Range:

$1.925

$2.1725

52-Week Range:

$1.32

$3.19

Protalix BioTherapeutics Inc. Stock (PLX) Company Profile

Name

Protalix BioTherapeutics Inc.

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

972 4 988 9488

Address

2 Snunit Street, Science Park PO Box 455, Karmiel

Employee

190

Twitter

@Protalix_Bio

Next Earnings Date

2026-05-08

Latest SEC Filings

PLX's Discussions on Twitter

Compare PLX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PLX Protalix BioTherapeutics Inc.	1.96	157.92M	52.74M	-6.60M	-13.63M	-0.0845
VRTX Vertex Pharmaceuticals Inc	424.36	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.06B	5.36B	287.73M	924.18M	2.5229

Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-08-20	Reiterated	H.C. Wainwright	Buy
Apr-17-17	Reiterated	Rodman & Renshaw	Buy
Apr-04-16	Initiated	Rodman & Renshaw	Buy
Apr-23-15	Upgrade	Jefferies	Hold → Buy
Nov-12-14	Reiterated	R. F. Lafferty	Buy
Jan-24-14	Initiated	R. F. Lafferty	Buy
May-02-12	Downgrade	Canaccord Genuity	Buy → Hold
May-02-12	Reiterated	Oppenheimer	Outperform
Apr-30-12	Downgrade	Auriga	Buy → Hold
Oct-13-11	Initiated	Morgan Joseph	Hold
Mar-17-11	Downgrade	WBB Securities	Strong Buy → Buy
Nov-09-10	Reiterated	Oppenheimer	Outperform
Oct-14-10	Reiterated	UBS	Buy
Dec-02-09	Reiterated	Hapoalim	Outperform
Sep-22-09	Initiated	Canaccord Adams	Buy
Sep-02-09	Initiated	Hapoalim	Outperform
Dec-01-08	Reiterated	Oppenheimer	Outperform
Mar-11-08	Initiated	UBS	Buy
Nov-20-07	Initiated	CIBC Wrld Mkts	Sector Outperform

View All

Protalix BioTherapeutics Inc. Stock (PLX) Latest News

Apr 30, 2026

Protalix BioTherapeutics (PLX) sets 2026 director, pay and stock plan votes - Stock Titan

Apr 30, 2026

Apr 27, 2026

Protalix says EU panel recommended a new dosing regimen for Fabry disease therapy - MSN

Apr 27, 2026

Protalix CFO updates Form 3 share and option holdings | PLX Insider Trading - Stock Titan

Apr 27, 2026

Apr 24, 2026

PLX News | PROTALIX BIOTHERAPEUTICS INC (NYSEARCA:PLX) - ChartMill

Apr 24, 2026

Apr 21, 2026

Protalix BioTherapeutics (NYSE:PLX) Stock Price Down 2.2%Here's Why - MarketBeat

Apr 21, 2026

Apr 19, 2026

Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025 - Quantisnow

Apr 19, 2026

Apr 15, 2026

Protalix: Elfabrio Struggles Against Oral Competition (NYSE:PLX) - Seeking Alpha

Apr 15, 2026

Apr 13, 2026

Aug Chart Watch: Is Protalix BioTherapeutics Inc currently under institutional pressure2026 Growth vs Value & Fast Moving Stock Watchlists - baoquankhu1.vn

Apr 13, 2026

Apr 10, 2026

PLX Stock Price, Quote & Chart | PROTALIX BIOTHERAPEUTICS INC (NYSEARCA:PLX) - ChartMill

Apr 10, 2026

Apr 08, 2026

Is Protalix (PLX) Stock entering maturity stage | Price at $2.26, Up 3.20%Senior Analyst Forecasts - Xã Vĩnh Công

Apr 08, 2026

Apr 07, 2026

Targets Report: What is Protalix BioTherapeutics Incs valuation compared to sectorIPO Watch & Risk Controlled Daily Trade Plans - baoquankhu1.vn

Apr 07, 2026

Apr 05, 2026

MACD Signal: Is Protalix BioTherapeutics Inc a top pick in the sector2026 Trading Volume Trends & Weekly High Return Forecasts - baoquankhu1.vn

Mar 31, 2026

Protalix targets $78M–$83M 2026 revenue with EU milestone, advancing PRX-115 - MSN

Mar 31, 2026

Mar 30, 2026

MAK Capital, Michael Kaufman report 3.62M‑share PLX stake (PLX) - Stock Titan

Mar 30, 2026

Mar 27, 2026

Aug Opening: What is Protalix BioTherapeutics Incs valuation compared to sector2026 Retail Activity & AI Based Trade Execution Alerts - baoquankhu1.vn

Mar 27, 2026

Mar 25, 2026

Volume Summary: Will Protalix BioTherapeutics Inc benefit from rising consumer demandPortfolio Risk Report & Long Hold Capital Preservation Tips - baoquankhu1.vn

Mar 25, 2026

Analyst Downgrade: Should I add Protalix BioTherapeutics Inc stock to my portfolio2026 Top Gainers & Real-Time Chart Pattern Alerts - baoquankhu1.vn

Mar 25, 2026

Mar 24, 2026

Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance (NYSE:PLX) - Seeking Alpha

Mar 24, 2026

Mar 23, 2026

Zacks Research Has Bullish Estimate for PLX FY2026 Earnings - MarketBeat

Mar 23, 2026

HC Wainwright Issues Negative Outlook for PLX Earnings - marketbeat.com

Mar 23, 2026

Mar 22, 2026

Can Protalix BioTherapeutics Inc lead its sector in growth2026 Growth vs Value & Weekly Top Gainers Alerts - baoquankhu1.vn

Mar 22, 2026

If You Invested $1,000 in Protalix Biother (PLX) - Stock Titan

Mar 22, 2026

Mar 21, 2026

A Look At Protalix BioTherapeutics (PLX) Valuation After Elfabrio Dosing Approval And Updated 2026 Revenue Guidance - Sahm

Mar 21, 2026

Mar 20, 2026

Research Analysts Issue Forecasts for PLX FY2026 Earnings - MarketBeat

Mar 20, 2026

Stock Market Recap: Is Cirrus Logic Inc forming a bullish divergenceRate Hike & High Win Rate Trade Alerts - baoquankhu1.vn

Mar 20, 2026

Mar 19, 2026

PLX: HC Wainwright & Co. Reiterates Buy Rating with $12 Target | - GuruFocus

Mar 19, 2026

Protalix BioTherapeutics (NYSE:PLX) Receives "Buy" Rating from HC Wainwright - MarketBeat

Mar 19, 2026

Protalix BioTherapeutics (PLX) TTM Loss Challenges Bullish Profitability Narratives After FY 2025 Results - simplywall.st

Mar 19, 2026

Mar 18, 2026